Evofem Biosciences Inc.

0.3719+0.0539+16.95%Vol 91.28M1Y Perf -73.50%
Jun 24th, 2022 16:00 DELAYED
BID0.3750 ASK0.3800
Open0.3261 Previous Close0.3180
Pre-Market- After-Market0.38
 - -  0.01 3.41%
Target Price
16.49 
Analyst Rating
Moderate Buy 1.83
Potential %
4.33K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
     31.62
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.53 
Earnings Rating
Sell
Market Cap13.16M 
Earnings Date
10th Aug 2022
Alpha-0.02 Standard Deviation0.39
Beta0.07 

Today's Price Range

0.32010.4900

52W Range

0.275018.60

5 Year PE Ratio Range

-0.9000-0.2000

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
20.83%
1 Month
3.31%
3 Months
-0.27%
6 Months
-19.15%
1 Year
-73.50%
3 Years
-93.82%
5 Years
-97.33%
10 Years
-

TickerPriceChg.Chg.%
EVFM0.37190.053916.95
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
0.00
0.10
0.78
8.72
-
Leverage Ratio -0.90
ProfitabilityValueIndustryS&P 500US Markets
59.50
-1 324.50
-1 314.90
-
-
RevenueValueIndustryS&P 500US Markets
11.39M
0.32
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-2.99-2.883.68
Q04 2021-3.45-4.95-43.48
Q03 2021-4.50-4.353.33
Q02 2021-5.25-4.0522.86
Q01 2021-7.35-8.40-14.29
Q04 2020-5.40-7.50-38.89
Q03 2020-0.44-0.3325.00
Q02 2020-0.37-0.39-5.41
Earnings Per EndEstimateRevision %Trend
6/2022 QR-2.78-2.96Negative
9/2022 QR-2.30-9.52Negative
12/2022 FY-10.00-2.56Negative
12/2023 FY-2.8641.63Positive
Next Report Date10th Aug 2022
Estimated EPS Next Report-2.78
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume91.28M
Shares Outstanding35.38K
Shares Float35.19M
Trades Count66.24K
Dollar Volume38.40M
Avg. Volume3.54M
Avg. Weekly Volume2.13M
Avg. Monthly Volume4.47M
Avg. Quarterly Volume4.02M

Evofem Biosciences Inc. (NASDAQ: EVFM) stock closed at 0.3719 per share at the end of the most recent trading day (a 16.95% change compared to the prior day closing price) with a volume of 91.28M shares and market capitalization of 13.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Evofem Biosciences Inc. CEO is Saundra Pelletier.

The one-year performance of Evofem Biosciences Inc. stock is -73.5%, while year-to-date (YTD) performance is -0.96%. EVFM stock has a five-year performance of -97.33%. Its 52-week range is between 0.275 and 18.6, which gives EVFM stock a 52-week price range ratio of 0.53%

Evofem Biosciences Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 8.37, a price-to-sale (PS) ratio of 0.96, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -312.73%, a ROC of -146.30% and a ROE of 272.46%. The company’s profit margin is -%, its EBITDA margin is -1 314.90%, and its revenue ttm is $11.39 Million , which makes it $0.32 revenue per share.

Of the last four earnings reports from Evofem Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-2.78 for the next earnings report. Evofem Biosciences Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Evofem Biosciences Inc. is Moderate Buy (1.83), with a target price of $16.49, which is +4 333.99% compared to the current price. The earnings rating for Evofem Biosciences Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evofem Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evofem Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.58, ATR14 : 0.07, CCI20 : 140.74, Chaikin Money Flow : -0.18, MACD : -0.05, Money Flow Index : 78.75, ROC : 3.48, RSI : 47.39, STOCH (14,3) : 45.07, STOCH RSI : 1.00, UO : 40.28, Williams %R : -54.93), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evofem Biosciences Inc. in the last 12-months were: Alexander A. Fitzpatrick (Buy at a value of $9 725), Justin J. File (Buy at a value of $15 020), Saundra Pelletier (Buy at a value of $100 328)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Summary RatingModerate Buy
1.83
Moderate Buy
1.83
Moderate Buy
1.83

Evofem Biosciences Inc.

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its focus is to advance the quality of life for women by developing solutions such as hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections. Its first commercial product, Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel, is for the prevention of pregnancy. Phexxi is hormone-free, female-controlled, on-demand prescription contraceptive gel. Its pipeline product candidate, EVO100, is being evaluated for the prevention of chlamydia and gonorrhea - two of the pervasive sexually transmitted diseases in the United States.

CEO: Saundra Pelletier

Telephone: +1 858 550-1900

Address: 12400 High Bluff Drive, San Diego 92130, CA, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

59%41%

Bearish Bullish

59%41%

News

Stocktwits